miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
Mango oil may inhibit DKK1 and DHT, potentially aiding hair growth by activating the Wnt signaling pathway. A user plans to test mango leaves juice and other Ayurvedic products for hair regrowth.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.
A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
The conversation discusses the effectiveness of combining Laminaria japonica and Cistanche tubulosa extracts for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.
Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.
A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.
The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.
Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.
The user experienced side effects from ecklonia cava similar to those reported with finasteride, including depression, brain fog, anxiety, and testicular pain. Despite these issues, the user is still considering using topical finasteride in the future.
A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.
The conversation discusses the potential benefits of adding Vitamin B6 (P-5-P) to topical hair loss treatments like RU58841, finasteride, or minoxidil. The user suggests that Vitamin B6 might enhance these treatments by naturally lowering scalp prolactin.
Low-Level Laser Therapy (LLLT) for hair loss is effective but requires consistent use and device replacement every 1-2 years. The treatment is costly, and results may not be permanent without continued use.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.